Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brimonidine/dorzolamide/timolol - Laboratorios Sophia

Next Previous
Drug Profile

Brimonidine/dorzolamide/timolol - Laboratorios Sophia

Alternative Names: Krytantek PF; PRO-122

Latest Information Update: 23 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Laboratorios Sophia
  • Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Quinoxalines; Small molecules; Sulfonamides; Thiadiazoles; Thiophenes
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Beta-adrenergic receptor antagonists; Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ocular hypertension

Most Recent Events

  • 08 Nov 2018 Chemical structure information added
  • 04 Aug 2017 Laboratorios Sophia S.A de C.V. initiates the phase III PRO-122LATAM trial in Ocular hypertension in Mexico (Ophthalmic) (NCT03193333)
  • 04 Aug 2017 Clinical trials in Ocular hypertension in Mexico (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top